Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-26. Numbers and descriptions here follow the published literature rather than marketing material.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Blood factors (Factor VIII and Factor IX) Thrombolytic agents (tissue plasminogen activator) Hormones (insulin, glucagon, growth hormone, gonadotrophins) Haematopoietic growth factors (Erythropoietin, colony-stimulating factors) Interferons (Interferons-α, -β, -γ) Interleukin-based products (Interleukin-2) Vaccines (Hepatitis B surface antigen) Monoclonal antibodies (Various) Additional products (tumour necrosis factor, therapeutic enzymes) Research and development investment in new medicines by the biopharmaceutical industry stood at $65.2 billion in 2008. A few examples of biologics made with recombinant DNA technology include: Many vaccines are grown in tissue cultures. Viral gene therapy involves artificially manipulating a virus to include a desirable piece of genetic material. Viral gene therapies using engineered plant viruses have been proposed to enhance crop performance and promote sustainable production.
In January 2021, the aromaticity has been observed in a large metal cluster anion consisting of 12 bismuth atoms stabilised by a center thorium cation. This compound was shown to be surprisingly stable, unlike many previous known aromatic metal clusters.
Insulin glargine/lixisenatide, sold under the brand name Soliqua among others, is a fixed-dose combination medication that combines insulin glargine and lixisenatide and is used to treat diabetes. The most common side effects include hypoglycemia (low blood glucose), diarrhea, vomiting and nausea (feeling sick). Insulin glargine/lixisenatide was approved for medical use in the United States in November 2016, and in the European Union in January 2017.
Sources: en.wikipedia.org
Human chorionic gonadotropin injection is extensively used for final maturation induction in lieu of luteinizing hormone. In the presence of one or more mature ovarian follicles, ovulation can be triggered by the administration of HCG. As ovulation will happen between 38 and 40 hours after a single HCG injection, procedures can be scheduled to take advantage of this time sequence, such as intrauterine insemination or sexual intercourse. Also, patients that undergo IVF, in general, receive HCG to trigger the ovulation process, but have an oocyte retrieval performed at about 34 to 36 hours after injection, a few hours before the eggs actually would be released from the ovary. As hCG supports the corpus luteum, administration of hCG is used in certain circumstances to enhance the production of progesterone. Several vaccines against human chorionic gonadotropin (hCG) for the prevention of pregnancy are currently in clinical trials.
== Side effects == Skin lightening creams have commonly contained mercury, hydroquinone, and corticosteroids. Because these compounds can induce both superficial and internal side effects, they are illegal to use and market in multiple nations. However, various chemical studies indicate that these compounds continue to be used in sold cosmetic products, though they are not explicitly declared as ingredients. Prolonged usage of mercury-based products can ultimately discolor the skin, as mercury will accumulate within the dermis. Mercury toxicity can cause acute symptoms such as pneumonitis and gastric irritation. However, according to a study by Antoine Mahé and his colleagues, mercurial compounds can also contribute to long-term renal and neurological complications, the latter of which includes insomnia, memory loss, and irritability. Other studies have explored the impact of hydroquinone exposure on health. Hydroquinone rapidly absorbs into the body via dermal contact; long-term usage has been found to cause nephrotoxicity and benzene-induced leukemia in the bone marrow. A study by Pascal del Giudice and Pinier Yves indicated that hydroquinone usage is strongly correlated with the development of ochronosis, cataracts, patchy depigmentation, and contact dermatitis. Ochronosis can lead to lesions and squamous cell carcinomas. While hydroquinone has not been officially classified as a carcinogen, it can metabolize into carcinogenic derivatives and induce genetic changes in the form of DNA damages.
Our politics seems more vulnerable to conspiracy theories and outright fabrication." He continued, "Bigotry in any form is blasphemy against the American creed and it means the very identity of our nation depends on the passing of civic ideals to the next generation", while urging citizens to oppose threats to American democracy and be positive role models for young people. The speech was widely interpreted as a denouncement of Donald Trump and his ideologies, despite Bush not mentioning Trump by name. On September 1, 2018, Bush and his wife attended the funeral of John McCain at the Washington National Cathedral in Washington, D.C. where Bush delivered remarks at the service. On November 30, his father died at his home. Shortly before his death, Bush was able to talk with his father on the phone; his father responded with what would be his last words, "I love you too". Bush attended his father's funeral on December 5, delivering a eulogy. In May 2019, on the tenth anniversary of former South Korean president Roh Moo-hyun's death, Bush visited South Korea to pay his respects to Roh, delivering a short eulogy. On June 1, 2020, Bush released a statement addressing the murder of George Floyd and the subsequent nationwide reaction and protests. In the statement, Bush wrote that he and former first lady Laura Bush "are anguished by the brutal suffocation of George Floyd and disturbed by the injustice and fear that suffocate our country".
Sources: en.wikipedia.org
The 1974 Carnation Revolution in Portugal, which over the next year replaced Portuguese support for Smith with an independent, Marxist–Leninist Mozambique on Rhodesia's eastern frontier, greatly swung the war's momentum in favour of the nationalists (particularly ZANU, which was allied with Mozambique's governing FRELIMO party), and caused the sanctions on Rhodesia to finally begin having a noticeable effect. Diplomatic isolation, the sanctions, guerrilla activities and pressure from South Africa to find a settlement led the Rhodesian government to hold talks with the various black Rhodesian factions. Abortive conferences were held at Victoria Falls (in 1975) and Geneva (1976). Despite ideological and tribal rifts, ZANU and ZAPU nominally united as the "Patriotic Front" (PF) in late 1976 in a successful attempt to augment overseas support for the black Rhodesian cause. By the mid-1970s, it was apparent that white minority rule could not continue forever. Even South Africa's prime minister John Vorster realized that white rule in a country where blacks outnumbered whites 22:1 was not a realistic option. Smith, who was decisively re-elected three times during the 1970s, eventually came to this conclusion as well. He announced his acceptance in principle of one man, one vote during Henry Kissinger's Anglo-American initiative in September 1976, and in March 1978 concluded the Internal Settlement with non-militant nationalist groups headed by Bishop Abel Muzorewa, the Reverend Ndabaningi Sithole and Chief Jeremiah Chirau.
=== Juvenile breast hypertrophy === When gigantomastia occurs in pubescent females, the medical condition is known as juvenile macromastia or juvenile gigantomastia and sometimes as virginal breast hypertrophy or virginal mammary hypertrophy although the term virginal is now considered misleading and outdated. Along with the excessive breast size, other symptoms include red, itchy lesions and pain in the breasts. A diagnosis is made when an adolescent's breasts grow rapidly and achieve great weight, usually soon after their first menstrual period. Some doctors suggest that the rapid breast development occurs before the onset of menstruation. Some adolescents with juvenile breast hypertrophy experience breast growth at a steady rate for several years, after which the breasts rapidly develop exceeding normal growth. Some adolescent females experience minimal or negligible breast growth until their breasts suddenly grow very rapidly in a short period of time. This may cause considerable physical discomfort. Individuals with JBH often experience an excessive growth of their nipples as well. In severe cases of JBH, clitoromegaly occurs. At the onset of puberty, some females who have experienced little or no breast development can reportedly reach three or more cup sizes within a few days (see below). As of 1992, 70 cases of juvenile breast hypertrophy had been reported.
=== Economics === The number of e-cigarettes sold increased every year from 2003 to 2014. As of 2014, there were at least 466 e-cigarette brands. Worldwide e-cigarette sales in 2014 were around US$7 billion. Worldwide e-cigarette sales in 2019 were about $19.3 billion. In 2021, the global e-cigarette market was estimated at about US$20.4 billion. In the United States, Reuters reported (citing Circana retail tracking reviewed by Reuters) that illegal sales of flavored disposable vapes reached about $2.4 billion in 2024 and accounted for roughly 35% of all e-cigarette sales in mainstream retail outlets tracked by Circana; Circana estimated the total tracked vape market at $6.8 billion, excluding online and specialty store sales. E-cigarette sales could exceed traditional cigarette sales by 2023.
Intensive airstrikes continued across Suwayda following the announcement of a ceasefire. The airstrikes targeted military equipment and convoys. One Syrian army convoy was struck in Suwayda, resulting in at least one casualty. The Mar Mikhael Church in the town of as-Sawra al-Kabira was robbed, vandalized, and burned. The group Men of Dignity announced over 50 of their members killed or injured in Suwayda clashes. On 16 July 2025, Sheikh Hikmat al-Hijri issued a statement, in which he appealed to Donald Trump, Benjamin Netanyahu, Mohammed bin Salman and Abdullah II to save Suwayda, stating that "the mask has fallen off the face of the ruling clique" and declaring, "we can no longer live with a regime that knows nothing of governance except iron and fire". Israel conducted airstrikes on several government buildings in Damascus, including the Syrian military headquarters, Israel Katz declared that the era of mere warnings in Damascus has ended, stating that "painful blows" will now be delivered to the Syrian government. Katz emphasized that the IDF will persistently and forcefully act in Suwayda to dismantle the forces responsible for attacking the Druze community until they fully withdraw. Addressing the Druze community in Israel, he reassured them that they can rely on the Israel Defense Forces for protection of their brethren in Syria, affirming that both he and Prime Minister Netanyahu have made a firm commitment to uphold this promise, The Syrian Ministry of Health reported three killed and 34 injured as a result of the attacks.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.